Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (mini-CHOP Therapy) (21 days) for the treatment of non-hodgkin lymphoma (NHL) in patients aged greater than 80 or with significant co-morbidities. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities. Rituximab to be included in all CD20 positive patients.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2018-11-05 | Health Service Executive | Indication approved for reimbursement. |